Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies.
about
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control studyA tutorial on the use of instrumental variables in pharmacoepidemiology.Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Drug-induced mitochondrial dysfunction and cardiotoxicity.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study.Cardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewDipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review.Instrumental Variable Methods for Continuous Outcomes That Accommodate Nonignorable Missing Baseline Values.Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trialRegardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.Incretins and pancreatitis--what happens next? A personal viewpoint.Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.
P2860
Q26752255-3D903B37-14E5-4370-806E-6185276BA100Q28534542-095F4C76-153D-49ED-A4B7-078BC26581E6Q30235546-5160D0D7-45A8-444D-A7C6-2B31BAF502AEQ31143283-1B67DCFA-3250-4872-A914-11BDB068F67FQ35073584-3A252128-4C46-44C3-85E8-46788C49DCAAQ36339445-661FB6C8-CCE9-4C92-A33D-61E97B2A1222Q37097189-3E7AC17A-2D32-4749-A757-226E62B73294Q37145172-D629D955-725E-4233-9C3A-08EE0311B437Q37361386-D743D383-8BA4-47D1-A560-D6B2B8146C38Q38215452-4EB2AFDA-2282-4B29-A984-00F44F66D600Q38258938-E14C410F-5B13-4200-A6AD-42D50778230BQ38364806-0982B064-7B9F-4FF8-B0C2-798C7D134540Q38396629-FE8B05C7-9DC4-4E7F-8C58-221BF74EA5D4Q38879500-F7197BF4-288B-4CE3-AB9B-8ECD40206D16Q38907817-18C7B4FD-6BAC-4572-A993-93E39660E88DQ38962521-78352284-85F4-4064-A821-B785CB689330Q39136054-381D2A58-F32B-4508-82EE-1F7D91AFB9C5Q39420208-88BE6FCD-3C6B-4B5A-8A74-6F86BC415F77Q40498481-4FF8EDEA-8A03-4380-9924-CF86E84F114DQ40787120-5B3EEBB0-09FB-445C-B724-FBD2EF09BD62Q40844288-C332A4D3-89A5-49F9-AEAF-9B59355BBF03Q42650180-BCCE230E-3682-49B1-B8C2-5DB6E36488E2Q44127740-8241A1CD-951F-419C-999E-B33512C33667Q45342248-8A42F704-BCAC-46A4-A756-D7107291185EQ47419443-4CE12D25-031F-4D10-8429-7F51DBD4A933Q48296438-146149D5-3278-4BB7-BEDD-DF3DE08786AC
P2860
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Association of sulphonylurea t ...... ysis of observational studies.
@en
type
label
Association of sulphonylurea t ...... ysis of observational studies.
@en
prefLabel
Association of sulphonylurea t ...... ysis of observational studies.
@en
P2093
P2860
P356
P1476
Association of sulphonylurea t ...... ysis of observational studies.
@en
P2093
Axel Haupt
Gero Schwenk
Guido Moeser
Stephan Jacob
Thomas Forst
P2860
P304
P356
10.1177/1479164112465442
P407
P577
2013-01-04T00:00:00Z